Daniel Devine & Co reduced its position in Astrazeneca PLC (NYSE:AZN) by 12.4% during the second quarter, Holdings Channel reports. The firm owned 37,400 shares of the company’s stock after selling 5,300 shares during the period. Astrazeneca PLC comprises about 1.0% of Daniel Devine & Co’s investment portfolio, making the stock its 23rd largest position. Daniel Devine & Co’s holdings in Astrazeneca PLC were worth $1,275,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently made changes to their positions in the company. Salem Investment Counselors Inc. bought a new position in shares of Astrazeneca PLC during the first quarter worth approximately $107,000. Meeder Asset Management Inc. bought a new position in shares of Astrazeneca PLC during the second quarter worth approximately $105,000. Tompkins Financial Corp boosted its position in shares of Astrazeneca PLC by 67.0% in the first quarter. Tompkins Financial Corp now owns 3,545 shares of the company’s stock worth $100,000 after buying an additional 1,422 shares during the period. Tower Research Capital LLC TRC boosted its position in shares of Astrazeneca PLC by 3,782.0% in the first quarter. Tower Research Capital LLC TRC now owns 3,882 shares of the company’s stock worth $121,000 after buying an additional 3,782 shares during the period. Finally, CENTRAL TRUST Co boosted its position in shares of Astrazeneca PLC by 2.1% in the first quarter. CENTRAL TRUST Co now owns 4,499 shares of the company’s stock worth $140,000 after buying an additional 91 shares during the period. 14.01% of the stock is currently owned by institutional investors and hedge funds.
Shares of Astrazeneca PLC (NYSE AZN) traded up 0.47% during trading on Friday, hitting $34.05. The stock had a trading volume of 3,602,670 shares. Astrazeneca PLC has a 12-month low of $25.55 and a 12-month high of $35.60. The stock has a market cap of $86.21 billion, a price-to-earnings ratio of 25.51 and a beta of 0.77. The stock’s 50-day moving average is $34.22 and its 200-day moving average is $31.14.
Astrazeneca PLC (NYSE:AZN) last announced its earnings results on Thursday, April 27th. The company reported $0.99 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.61. Astrazeneca PLC had a net margin of 15.21% and a return on equity of 35.65%. The business had revenue of $5.41 billion during the quarter, compared to the consensus estimate of $5.40 billion. During the same quarter in the prior year, the firm earned $0.95 earnings per share. The business’s quarterly revenue was down 11.6% compared to the same quarter last year. On average, equities research analysts expect that Astrazeneca PLC will post $1.85 EPS for the current year.
Several research firms have recently issued reports on AZN. UBS AG cut Astrazeneca PLC from a “buy” rating to a “neutral” rating and reduced their target price for the company from $35.44 to $25.55 in a research note on Wednesday, April 5th. BidaskClub cut Astrazeneca PLC from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. Zacks Investment Research cut Astrazeneca PLC from a “strong-buy” rating to a “sell” rating in a research note on Monday, July 17th. Barclays PLC reissued an “overweight” rating on shares of Astrazeneca PLC in a research note on Thursday, July 13th. Finally, Jefferies Group LLC reissued a “hold” rating on shares of Astrazeneca PLC in a research note on Monday, April 10th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $34.13.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.
